Journal of hepatology · 2026
Arachidonoyl-taurine is elevated in human MASLD and protects against hepatic steatosis and inflammation in preclinical models.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kuentzel Katharina B, Trammell Samuel A J, Hassing Anna S, Bradić Ivan, Damgaard Michelle, Fals Emma B, Michler Katja T, Dooley Matthew, Jacobsen Jens C B, Suppli Malte P, Werge Mikkel P, Mitchell Cameron J, Wewer Albrechtsen Nicolai J, Glud Lise L, Knop Filip K, Markworth James F, Larsen Martin R, Gillum Matthew P, Treebak Jonas T, Dalli Jesmund, Larsen Steen, Grevengoed Trisha J
Аннотация
BACKGROUND & AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH), represent a global health challenge intricately linked to lipid dysregulation and systemic inflammation. Identifying biomarkers and causative molecules involved in disease progression is therefore essential. N-acyl taurines (NATs) are endogenous metabolites involved in whole-body metabolic regulation, but their roles in liver disease have not been elucidated.
METHODS: To study the relationship between NATs and MASLD, we analyzed NAT profiles in human blood samples from individuals with clinical MASLD or short-term overfeeding-induced hepatic steatosis. Mouse models of MASLD and MASH were used to determine the effects of these alterations and to investigate the underlying mechanisms of action.
RESULTS: We identified an endogenous, uncharacterized arachidonic acid (ARA)-derived metabolite, arachidonoyl-taurine (ARA-T), capable of mitigating steatotic liver disease and reducing hepatic inflammation. ARA-T levels increased in human plasma from individuals with chronic and overfeeding-induced liver steatosis, and its abundance was increased in both humans and mice by dietary ARA supplementation. Despite ARA's association with pro-inflammatory mediators, administration of ARA-T reduced hepatic lipid deposition and inflammation. Chronic elevation through genetic and dietary models mitigated the development of steatosis and fibrosis through increased hepatic oxidation of fatty acids.
CONCLUSIONS: ARA-T is an endogenous metabolite that increases with human hepatic steatosis and reduces murine hepatic lipid content independent of weight loss, demonstrating its direct action and potential to reverse the progression of liver disease.
IMPACT AND IMPLICATIONS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is among the most prevalent forms of liver disease worldwide and is likely to affect more than half of the global population in the next decade, with limited treatment options available. Here, we identified an endogenous, uncharacterized omega-6 fatty acid metabolite, arachidonoyl-taurine (ARA-T), capable of mitigating steatotic liver disease and reducing hepatic inflammation by increasing hepatic fatty acid oxidation. This study positions ARA-T as an endogenous molecule with hepatoprotective effects and a potential therapeutic target for MASLD.
METHODS: To study the relationship between NATs and MASLD, we analyzed NAT profiles in human blood samples from individuals with clinical MASLD or short-term overfeeding-induced hepatic steatosis. Mouse models of MASLD and MASH were used to determine the effects of these alterations and to investigate the underlying mechanisms of action.
RESULTS: We identified an endogenous, uncharacterized arachidonic acid (ARA)-derived metabolite, arachidonoyl-taurine (ARA-T), capable of mitigating steatotic liver disease and reducing hepatic inflammation. ARA-T levels increased in human plasma from individuals with chronic and overfeeding-induced liver steatosis, and its abundance was increased in both humans and mice by dietary ARA supplementation. Despite ARA's association with pro-inflammatory mediators, administration of ARA-T reduced hepatic lipid deposition and inflammation. Chronic elevation through genetic and dietary models mitigated the development of steatosis and fibrosis through increased hepatic oxidation of fatty acids.
CONCLUSIONS: ARA-T is an endogenous metabolite that increases with human hepatic steatosis and reduces murine hepatic lipid content independent of weight loss, demonstrating its direct action and potential to reverse the progression of liver disease.
IMPACT AND IMPLICATIONS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is among the most prevalent forms of liver disease worldwide and is likely to affect more than half of the global population in the next decade, with limited treatment options available. Here, we identified an endogenous, uncharacterized omega-6 fatty acid metabolite, arachidonoyl-taurine (ARA-T), capable of mitigating steatotic liver disease and reducing hepatic inflammation by increasing hepatic fatty acid oxidation. This study positions ARA-T as an endogenous molecule with hepatoprotective effects and a potential therapeutic target for MASLD.